Mass. Movers

Insulet boosts sales, narrows its net loss

A patient with diabetes tests his blood.

A patient with diabetes tests his blood.


Insulet Corp. soared as the Bedford company posted quarterly results. Revenue increased 20 percent to $57.4 million from a year earlier, and gross profit was up 24 percent to $25.2 million. Those increases, the company said, were driven by sales of the new, smaller, and lighter OmniPod Insulin Management System for diabetics, launched in the United States in February. Insulet’s net loss was $10.7 million, or $0.20 per share, compared to a net loss of $14.8 million, or $0.31, a year earlier.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of